Back to Newsroom
Back to Newsroom

Xtant Medical Receives FDA 510(K) Clearance for InTice(TM)-C Porous Titanium Cervical Interbody System

Monday, 21 May 2018 07:30 AM

Xtant Medical Holdings, Inc.

BELGRADE, MT / ACCESSWIRE / May 21, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody System.

InTice-C is designed using OsteoSync Ti, a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely resembles the bioscaffold of cancellous bone, and further combines Xtant Medical's hardware and biologic portfolios. In addition to InTice-C serving as a bioactive scaffold, it is also cleared for use with Xtant's proprietary allograft lines, including OsteoSponge®, 3Demin® Cortical Fibers, and OsteoVive™ viable cell allograft.

"InTice-C represents Xtant's latest addition to our spinal implant portfolio and is our first spinal implant to be engineered using a best-in-class porous titanium material," stated Dr. Gregory Juda, Chief Scientific Officer and General Manager of Xtant Medical. "The porous architecture of the titanium was designed to improve implant fixation, both prior and post fusion. We expect a positive reception of this technology from our surgeon customers in the cervical spine market."

The InTice-C Is designed to provide cervical intervertebral body fusion options for each patient's varied anatomy. It is offered in multiple footprint, height and endplate options. The commercial pure titanium structure offers continuous pore interconnectivity from the top to the bottom as well as from the outer perimeter to the large central graft cavity of the implant. This optimizes vascularization to the fusion site allowing the implant to be a participant in the fusion process. The implant utilizes machined endplate structures in conjunction with the inherent texture of the porous titanium to provide migration resistance. The implant is offered in individual sterile packages. InTice-C was developed in collaboration with Sites Medical.

InTice-C will help the Company further penetrate the $285 million dollar cervical spine market. Xtant's other cervical interbody options include Calix®-C, Calix-C PC, Atrix-C®, and Irix®-C, which offer PEEK, PEEK with a plasma-coated titanium, a structural biologic solution, and a standalone cervical option, respectively.

About Xtant Medical

Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit

Important Cautions Regarding Forward-looking Statements

This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ''continue,'' ''efforts,'' ''expects,'' ''anticipates,'' ''intends,'' ''plans,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''strategy,'' ''will,'' ''goal,'' ''target,'' ''prospects,'' ''potential,'' ''optimistic,'' ''confident,'' ''likely,'' ''probable'' or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability to increase revenue; the ability to achieve expected results; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain qualified technical personnel and members of the Company's management team; influence by Company management; the security of our technology systems; government and third-party coverage and reimbursement for Company products; the ability to obtain donors to support the biologic portfolio; the availability of Company facilities; the ability to remain accredited with the American Association of Tissue Banks; the ability to obtain regulatory approvals; government regulations; product liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of intellectual property; the ability to use net operating loss carry-forwards to offset future taxable income; the ability to service Company debt; the ability to comply with covenants in the Company's senior credit facility; the ability to raise additional financing and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC) on April 2, 2018 and subsequent SEC filings by the Company, including without limitation its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. Investors are encouraged to read the Company's filings with the SEC, available at, for a discussion of these and other risks and uncertainties. Investors should not place considerable reliance on the forward-looking statements contained in this release. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. The Company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Investor Contact

Rich Cockrell
[email protected]

Company Contact

Xtant Medical
Molly Mason
[email protected]
Xtant Medical Holdings, Inc.

SOURCE: Xtant Medical Holdings, Inc.

Company Update
Back to newsroom
Back to Newsroom

Contact Us Today

If you have questions or want to learn more about our products, our team’s here to help!

Share by: